RNAi Therapeutics in Autoimmune Disease
AbstractSince the discovery of RNA interference (RNAi), excitement has grown over its potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change biological processes post-transcriptionally in various health conditions such as cancer or autoimmune diseases. Optimum design of shRNA, siRNA, and miRNA enhances stability and specificity of RNAi-based approaches whereas it has to reduce or prevent undesirable immune responses or off-target effects. Recent advances in understanding pathogenesis of autoimmune diseases have allowed application of these tools in vitro as well as in vivo with some degree of success. Further research on the design and delivery of effectors of RNAi pathway and underlying molecular basis of RNAi would warrant practical use of RNAi-based therapeutics in human applications. This review will focus on the approaches used for current therapeutics and their applications in autoimmune diseases, including rheumatoid arthritis and Sjögren’s syndrome. View Full-Text
Share & Cite This Article
Pauley, K.M.; Cha, S. RNAi Therapeutics in Autoimmune Disease. Pharmaceuticals 2013, 6, 287-294.
Pauley KM, Cha S. RNAi Therapeutics in Autoimmune Disease. Pharmaceuticals. 2013; 6(3):287-294.Chicago/Turabian Style
Pauley, Kaleb M.; Cha, Seunghee. 2013. "RNAi Therapeutics in Autoimmune Disease." Pharmaceuticals 6, no. 3: 287-294.